Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SGRL.NS
SellFallen FavouriteShree Ganesh Remedies Limited · Healthcare · India · $94M
21
StockRankGet insider-trade alerts
Q
63
V
22
M
22
P/E (TTM)
55.3x
ROE
10.9%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Shree Ganesh Remedies Limited engages in the manufacture and sale of pharmaceutical drug intermediates for active pharmaceutical ingredient (API) and fine chemicals in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 902.2M | 1.2B | 1.1B | 1.1B | 6.2% | 993.2M |
| EPS (INR) | 14.01 | 22.34 | 17.96 | 13.83 | -0.4% | 12.08 |
| Shares | 12.8M | 12.8M | 12.8M | 12.8M | -0.1% | 12.8M |
| Debt | 335.1M | 364.5M | 383.8M | 308.1M | -2.8% | 309.2M |
| Equity | 889.4M | 1.2B | 1.5B | 1.6B | 22.4% | — |
| Op CF | 170.1M | 304.5M | 306.6M | 237.4M | 11.8% | 238.2M |
| Inv CF | -535.7M | -330.1M | -356.6M | -98.9M | — | — |
| Fin CF | 413.3M | 98.4M | -10.9M | -117.0M | — | — |
Loading 1Y...
PRICE (1Y)+27.0%
Close
$6.98
RSI (14)
78.6
SCORE BREAKDOWN
Quality
63
ROIC
12.8%78.3
ROE
10.9%73.0
GP/Assets
30.7%64.6
Op. Margin
6.3%55.3
FCF/Assets
3.4%62.5
Piotroski
549.3
Int. Cover
8.1x58.6
D/E Ratio
0.19x51.0
Current Ratio
3.96x65.1
Value
22
P/E (TTM)
55.3x19.5
EV/EBITDA
28.7x22.4
P/FCF
125.5x14.4
P/B
—N/A
P/S
8.6x28.5
Div Yield
—N/A
Momentum
22
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-68%5.8
FUNDAMENTALS
Market Cap
$94M
P/E (Forward)
—
Gross Margin
64.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGRL.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SGRL.NS | Shree Ganesh Remedies Limited(you) | $94M | 21 | Sell |
| SIGACHI.NS | Sigachi Industries Limited | $140M | 39 | Hold |
| SHUKRAPHAR.NS | Shukra Pharmaceuticals Limited | $252M | 38 | Hold |
| BAFNAPH.NS | Bafna Pharmaceuticals Limited | $77M | 55 | Hold |
| AMRUTANJAN.NS | Amrutanjan Health Care Limited | $153M | 53 | Hold |
| NOVARTIND.NS | Novartis India Limited | $475M | 30 | Sell |
| KILITCH.NS | Kilitch Drugs (India) Limited | $69M | 58 | Hold |
| BAJAJHCARE.NS | Bajaj HealthCare Limited | $120M | 59 | Hold |
| THEMISMED.NS | Themis Medicare Limited | $129M | 62 | Hold |
| WANBURY.NS | Wanbury Limited | $91M | 69 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%